ArticleHepatology international2024

Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.

Hyung-Don Kim et al.PubMed ↗Publisher ↗

No numbers read from the abstract.